Malaysia Hyaluronic Acid Market for Knee Osteoarthritis Treatment Size, Share and Trends Analysis Report – Industry Overview and Forecast to 2032

1 INTRODUCTION

1.1 OBJECTIVES OF THE STUDY

1.2 MARKET DEFINITION

1.3 OVERVIEW

1.4 LIMITATIONS

1.5 MARKETS COVERED

2 MARKET SEGMENTATION

2.1 MARKETS COVERED

2.2 GEOGRAPHICAL SCOPE

2.3 YEARS CONSIDERED FOR THE STUDY

2.4 CURRENCY AND PRICING

2.5 DBMR TRIPOD DATA VALIDATION MODEL

2.6 MULTIVARIATE MODELING

2.7 PRIMARY INTERVIEWS WITH KEY OPINION LEADERS

2.8 DBMR MARKET POSITION GRID

2.9 SECONDARY SOURCES

2.1 ASSUMPTIONS

3 EXECUTIVE SUMMARY

4 PREMIUM INSIGHTS

4.1 PORTER’S FIVE FORCES ANALYSIS

4.1.1 THREAT OF NEW ENTRANTS

4.1.2 BARGAINING POWER OF SUPPLIERS

4.1.3 BARGAINING POWER OF BUYERS

4.1.4 THREAT OF SUBSTITUTES

4.1.5 INTERNAL COMPETITION

4.2 PATENT ANALYSIS –

4.2.1 PATENT QUALITY AND STRENGTH

4.2.2 PATENT FAMILIES

4.2.3 NUMBER OF INTERNATIONAL PATENT FAMILIES BY PUBLICATION YEAR

4.2.4 IP STRATEGY AND MANAGEMENT

4.2.5 PATENT ANALYSIS – TOP APPLICANTS

4.3 COMPANY EVALUATION QUADRANT

4.4 CONSUMER BUYING BEHAVIOUR

4.4.1 GROUP 1: AFFLUENT PATIENTS IN PRIVATE HOSPITALS

4.4.2 GROUP 2: MIDDLE-CLASS PATIENTS IN SEMI-PRIVATE CLINICS

4.4.3 GROUP 3: INNOVATION-SEEKING PATIENTS & WELLNESS-ORIENTED BUYERS

4.4.4 GROUP 4: PUBLIC HOSPITAL PATIENTS WITH SUBSIDIZED ACCESS

4.4.5 GROUP 5: PRICE-SENSITIVE LOCAL CONSUMERS & SMES (RURAL/SMALL-TOWN PATIENTS)

4.4.6 GROUP 6: ESG-FOCUSED & HIGH-TECH CONSUMERS

4.5 BRAND OUTLOOK

4.5.1 BIOVENTUS

4.5.2 ANIKA THERAPEUTICS, INC

4.5.3 FIDIA FARMACEUTICI S.P.A.

4.5.4 SANOFI

4.5.5 SEIKAGAKU CORPORATION

4.6 INNOVATION TRACKER AND STRATEGIC ANALYSIS

4.6.1 MAJOR DEALS AND STRATEGIC ALLIANCES ANALYSIS

4.6.2 JOINT VENTURES

4.6.3 MERGERS AND ACQUISITIONS

4.6.4 LICENSING AND PARTNERSHIP

4.6.5 TECHNOLOGY COLLABORATIONS

4.6.6 STRATEGIC DIVESTMENTS

4.6.7 NUMBER OF PRODUCTS IN DEVELOPMENT

4.6.8 STAGE OF DEVELOPMENT

4.6.9 TIMELINES AND MILESTONES

4.6.10 INNOVATION STRATEGIES AND METHODOLOGIES

4.6.11 RISK ASSESSMENT AND MITIGATION

4.6.12 FUTURE OUTLOOK

4.7 TECHNOLOGICAL ADVANCEMENTS

4.7.1 NEXT-GEN HA CHEMISTRIES: CROSS-LINKING, MOLECULAR-WEIGHT TUNING, AND SINGLE-INJECTION DURABILITY

4.7.2 PRECISION DELIVERY: ULTRASOUND-GUIDED TECHNIQUES, SMART SYRINGES, AND PROCEDURAL STANDARDIZATION

4.7.3 COMBINATION AND ADJUNCTIVE BIOLOGICS: HA + PRP, BUFFERED CORTICOSTEROID BRIDGES, AND REHAB-INTEGRATED CARE

4.7.4 MANUFACTURING, STERILITY, AND COLD-CHAIN MODERNIZATION: QUALITY BY DESIGN FOR CONSISTENT PERFORMANCE

4.8 VALUE CHAIN ANALYSIS

4.8.1 RAW MATERIAL PROCUREMENT

4.8.2 RESEARCH & DEVELOPMENT (R&D)

4.8.3 PRODUCT DESIGN AND PROTOTYPING

4.8.4 MANUFACTURING AND ASSEMBLY

4.8.5 REGULATORY APPROVALS AND QUALITY ASSURANCE

4.8.6 DISTRIBUTION AND LOGISTICS

4.8.7 MARKETING AND SALES

4.8.8 TRAINING AND TECHNICAL SUPPORT

4.8.9 AFTER-SALES SERVICE AND FEEDBACK INTEGRATION

5 TARIFFS & IMPACT ON THE MARKET

5.1 CURRENT TARIFF RATE (S) IN TOP-5 COUNTRY MARKETS

5.2 OUTLOOK: LOCAL PRODUCTION V/S IMPORT RELIANCE

5.3 VENDOR SELECTION CRITERIA DYNAMICS

5.4 IMPACT ON SUPPLY CHAIN

5.4.1 RAW MATERIAL PROCUREMENT

5.4.2 MANUFACTURING AND PRODUCTION

5.4.3 LOGISTICS AND DISTRIBUTION

5.4.4 PRICE PITCHING AND POSITION OF MARKET

5.5 INDUSTRY PARTICIPANTS: PROACTIVE MOVES

5.6 SUPPLY CHAIN OPTIMIZATION

5.6.1 JOINT VENTURE ESTABLISHMENTS

5.7 IMPACT ON PRICES

5.8 REGULATORY INCLINATION

5.8.1 GEOPOLITICAL SITUATION

5.8.2 TRADE PARTNERSHIPS BETWEEN THE COUNTRIES

5.8.2.1 FREE TRADE AGREEMENTS

5.8.2.2 ALLIANCES ESTABLISHMENTS

5.8.3 STATUS ACCREDITATION (INCLUDING MFTN)

5.8.4 DOMESTIC COURSE OF CORRECTION

5.8.4.1 INCENTIVE SCHEMES TO BOOST PRODUCTION OUTPUTS

5.8.4.2 ESTABLISHMENT OF SPECIAL ECONOMIC ZONES/INDUSTRIAL PARKS

5.9 CONCLUSION

6 REGULATION COVERAGE

6.1 OVERVIEW

6.2 CONCLUSION

7 MARKET OVERVIEW

7.1 DRIVERS

7.1.1 INCREASING PREVALENCE OF KNEE OSTEOARTHRITIS

7.1.2 GROWING PREFERENCE FOR MINIMALLY INVASIVE AND NON‑SURGICAL TREATMENT OPTIONS IN MALAYSIA

7.1.3 RECENT LAUNCHES OF HYALURONIC ACID FOR OSTEOARTHRITIS TREATMENT IN MALAYSIA

7.1.4 CLINICAL VALIDATION OF HYALURONIC ACID IN OSTEOARTHRITIS TREATMENT

7.2 RESTRAINTS

7.2.1 COMPETITION OF ALTERNATIVE THERAPIES FOR KNEE OSTEOARTHRITIS

7.2.2 HIGH COST AND INSURANCE CONSTRAINTS FOR HYALURONIC ACID THERAPY IN KNEE OSTEOARTHRITIS

7.3 OPPORTUNITIES

7.3.1 ADVANCEMENTS IN HYALURONIC ACID FORMULATIONS AND GROWING PREFERENCE FOR MINIMALLY INVASIVE TREATMENT OPTIONS

7.3.2 PROMOTING AWARENESS AND ACCEPTANCE OF HYALURONIC ACID FOR KNEE OSTEOARTHRITIS TREATMENT AMONG MALAYSIAN PHYSICIANS AND PATIENTS

7.3.3 COMBINATION OF HYALURONIC ACID WITH OTHER THERAPEUTIC OPTIONS FOR KNEE OSTEOARTHRITIS

7.4 CHALLENGES

7.4.1 SHORT-TERM BENEFITS WITH QUESTIONED CLINICAL EFFICACY OF HYALURONIC ACID FOR KNEE OSTEOARTHRITIS

7.4.2 REGULATORY HURDLES AND STRINGENT COMPLIANCE REQUIREMENTS

8 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY INJECTION REGIMEN

8.1 OVERVIEW

8.2 SINGLE INJECTION (MONOPHASIC)

8.3 THREE-INJECTION REGIMEN (TRIPHASIC)

8.4 FIVE-INJECTION REGIMEN (PENTAPHASIC)

9 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY CROSSLINKING

9.1 OVERVIEW

9.2 HIGHLY CROSS-LINKED HYALURONIC ACID

9.3 LIGHTLY CROSS-LINKED HYALURONIC ACID

9.4 NON-CROSS-LINKED HYALURONIC ACID

10 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY MOLECULAR WEIGHT

10.1 OVERVIEW

10.2 HIGH MOLECULAR WEIGHT (HMW) HA

10.3 LOW MOLECULAR WEIGHT (LMW) HA

10.4 MEDIUM MOLECULAR WEIGHT HA

11 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY JOINT TREATED

11.1 OVERVIEW

11.2 KNEE OSTEOARTHRITIS

11.3 HIP OSTEOARTHRITIS

11.4 SHOULDER OSTEOARTHRITIS

11.5 ANKLE OSTEOARTHRITIS

11.6 OTHERS

12 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY BRAND

12.1 OVERVIEW

12.2 DUROLANE

12.3 SYNVISC / SYNVISC

12.4 MONOVISC / ORTHOVISC

12.5 EUFLEXXA

12.6 OSTENIL / OSTENIL PLUS

12.7 LOCAL/REGIONAL BRANDS/OTHERS

13 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY AGE GROUP

13.1 OVERVIEW

13.2 60–75 YEARS

13.3 ABOVE 75 YEARS

13.4 BELOW 50 TO 59 YEARS

14 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY END USER

14.1 OVERVIEW

14.2 PRIVATE HOSPITALS

14.3 SPECIALIST ORTHOPEDIC CLINICS

14.4 GOVERNMENT HOSPITALS

14.5 GENERAL PRACTITIONERS

15 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT, BY DISTRIBUTION CHANNEL

15.1 OVERVIEW

15.2 DIRECT TENDER

15.3 RETAIL & ONLINE PHARMACIES

15.4 OTHERS

16 MALAYSIA HYALURONIC ACID MARKET FOR KNEE OSTEOARTHRITIS TREATMENT MARKET

16.1 COMPANY SHARE ANALYSIS: MALAYSIA

17 SWOT ANALYSIS

18 COMPANY PROFILE MANUFACTURER

18.1 SANOFI

18.1.1 COMPANY SNAPSHOT

18.1.2 REVENUE ANALYSIS

18.1.3 PRODUCT PORTFOLIO

18.1.4 RECENT DEVELOPMENT

18.2 BIOVENTUS

18.2.1 COMPANY SNAPSHOT

18.2.2 REVENUE ANALYSIS

18.2.3 PRODUCT PORTFOLIO

18.2.4 RECENT DEVELOPMENT

18.3 FIDIA FARMACEUTICI S.P.A.

18.3.1 COMPANY SNAPSHOT

18.3.2 REVENUE ANALYSIS

18.3.3 PRODUCT PORTFOLIO

18.3.4 RECENT DEVELOPMENT

18.4 FERRING

18.4.1 COMPANY SNAPSHOT

18.4.2 PRODUCT PORTFOLIO

18.4.3 RECENT DEVELOPMENT

18.5 ANIKA THERAPEUTICS, INC.

18.5.1 COMPANY SNAPSHOT

18.5.2 REVENUE ANALYSIS

18.5.3 PRODUCT PORTFOLIO

18.5.4 RECENT DEVELOPMENT

18.6 SEIKAGAKU CORPORATION

18.6.1 COMPANY SNAPSHOT

18.6.2 REVENUE ANALYSIS

18.6.3 PRODUCT PORTFOLIO

18.6.4 RECENT DEVELOPMENT

18.7 TRB CHEMEDICA INTERNATIONAL SA

18.7.1 COMPANY SNAPSHOT

18.7.2 PRODUCT PORTFOLIO

18.7.3 RECENT DEVELOPMENTS

19 QUESTIONNAIRE